Lithium for Parkinson's Disease

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: State University of New York at Buffalo

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.

Research Team

Eligibility Criteria

This trial is for early-stage Parkinson's disease patients who haven't used tobacco or THC for over a year, have had stable PD medications and psychiatric/diuretic meds for at least 30-60 days, and no history of lithium therapy. They should not have other medical conditions that could affect the study.

Inclusion Criteria

You have been diagnosed with Parkinson's Disease for less than four years by a movement disorder specialist, and you possess normal thyroid and renal function

I haven't used tobacco or THC for over a year and my Parkinson's disease medication has been stable for over 30 days.

You do not have any medical or mental health issues that could impede study activities, according to the investigator.

Treatment Details

Interventions

• Lithium aspartate (Other)

Trial Overview The study tests if low doses of lithium aspartate (30-45mg/day) can impact MRI brain scans and blood markers in people with early-stage Parkinson's Disease. It aims to enroll 15 participants to observe these potential changes.

Participant Groups

Group I: Lithium aspartate Experimental Treatment 1 Intervention

Lithium aspartate capsules will be titrated in each patient to the maximum tolerated dosage between 30-45mg/day.

Who Is Running the Clinical Trial?

State University of New York at Buffalo

Lead Sponsor

Trials

279

Recruited

52,600+

Dr. Jonathan Slonin

State University of New York at Buffalo

Chief Medical Officer since 2020

MD from University of Miami, MBA from George Washington University

Stacy Knapper

State University of New York at Buffalo

Chief Executive Officer since 2023

BSEE from University of Puerto Rico-Mayagüez, MS in Management from Rensselaer Polytechnic Institute

National Center for Advancing Translational Sciences (NCATS)

Collaborator

Trials

394

Recruited

404,000+

Dominique C. Pichard

National Center for Advancing Translational Sciences (NCATS)

Chief Medical Officer since 2023

MD

Joni L. Rutter

National Center for Advancing Translational Sciences (NCATS)

Chief Executive Officer since 2022

PhD in Pharmacology